A Study of a Wearable Vital Signs Monitoring Device for the Detection of Systemic Inflammatory Response Syndrome and Sepsis in Stem Cell Transplant Patients

Overview

About this study

The purpose of this study is to validate the effectiveness of the ZephyrLife Home monitoring device compared with standard ICU or stepdown vital signs monitoring,  especially for heart rate, respiratory rate and temperature as systemic (whole body) inflammatory response syndrome or sepsis ( whole body infection) markers in stem cell transplant patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years or over
  • History of stem cell transplantation
  • Has continuous vital signs monitoring in the ICU/step-down unit

Exclusion Criteria

  • Refusal to participate in the study
  • Agitation
  • Unable to consent or participate in the study
  • Attending physician on clinical service indicates that patient is not a candidate for the study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Ayan Sen, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20307736

Mayo Clinic Footer